Skip to main content
. 2020 Mar 15;12(3):268. doi: 10.3390/pharmaceutics12030268

Figure 4.

Figure 4

(A) Plasma and (B) kidney concentration vs. time profile of DWP16001 (●), dapagliflozin (▼), and ipragliflozin (○) after a single oral administrations of DWP16001, dapagliflozin, and ipragliflozin at a dose of 1 mg/kg in Institute of Cancer Research (ICR) mice, respectively. Data are expressed as mean±SD from five mice.